Why the study?
The study aimed to evaluate the clinical relevance of the parsimonious Eurolung risk scoring system for predicting postoperative morbidity, mortality, and long-term survival in Korean patients with surgically resected non-small cell lung cancer.
Does the parsimonious Eurolung risk scoring system predict postoperative morbidity, mortality, and long-term survival in Korean patients with surgically resected non-small cell lung cancer?
Does the parsimonious Eurolung risk scoring system predict postoperative morbidity, mortality, and long-term survival in Korean patients with surgically resected non-small cell lung cancer?
The parsimonious Eurolung risk scoring system demonstrates good discriminatory ability for predicting postoperative morbidity, mortality, and long-term survival in Korean patients undergoing surgery for non-small cell lung cancer.
May support Eurolung for risk stratification in Korean NSCLC; extends validation to Asian cohorts but leaves adoption open pending prospective data.
BACKGROUND: This study aimed to assess the clinical relevance of the parsimonious Eurolung risk scoring system for predicting postoperative morbidity, mortality, and long-term survival in Korean patients with surgically resected non-small cell lung cancer. METHODS: This retrospective analysis used the data of patients who underwent anatomical resection for non-small cell lung cancer between 2004 and 2018 at a single institution. The parsimonious aggregate Eurolung score was calculated for each patient. The Cox regression model was used to determine the ability of the Eurolung scoring system for predicting long-term outcomes. RESULTS: < 0.001). CONCLUSION: Stratification based on the parsimonious Eurolung scoring system showed good discriminatory ability for predicting postoperative morbidity, mortality, and long-term survival in South Korean patients with surgically resected non-small cell lung cancer. This might help clinicians to provide a detailed prognosis and decide the appropriate treatment option for high-risk patients with non-small cell lung cancer.
No takes yet. Share an insight, caveat, or question.
Yun et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: